Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)

• DOI: 10.1007/s13300-020-00945-4
• Publication Date: 2020-10-26T06:02:50Z
• Authors: Luciano Zenari; Andrea Da Porto; Lorena De Moliner; Francesca Lugli; Valeria Guazzoni; Gloria Groppelli; Laura Molteni; Massimo Bracaccia; Vera Frison; Natalino Simioni; Barbara Bonsembiante; Cesare Miranda; Annunziata Lapolla
• Keywords: Insulin degludec; Glycated hemoglobin; Concomitant; Combination therapy

Combination therapy with both basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is an effective treatment in patients uncontrolled type 2 diabetes mellitus (T2DM). The recent development release of a fixed-ratio combination slow-release degludec the GLP-1RA liraglutide (IDegLira) represents improvement to this therapy. We have conducted real-world evidence study Italian T2DM evaluate whether encouraging clinical trial results obtained IDegLira, which became available Italy January 2018, can be confirmed practice. This was multicenter, retrospective, observational treated IDegLira from December 2018. Prior initiation therapy, were BI or without one more concomitant oral antidiabetic drugs (BOT group) according bolus protocol (BI rapid-acting treatment; BB group). A total 244 included present study, whom 186 BOT group 58 group. Following switch glycemic control improved groups, significant reductions glycated hemoglobin after 6 12 months No gain body weight mass index fasting plasma glucose number diabetic medications (in patients) observed. All during achieved at moderate dose IDegLira. findings show that setting, valid option for who are failing achieve targets and/or struggling side effects, such as hypoglycemia, other therapies.